Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825976 | 0.85 | FABP4 (0.49) | EPHX2ALDH1A1FABP4FABP3FABP5 | |
| SCHEMBL5717023 | 0.80 | FKBP1A (0.52) | EPHX2LMNAALDH1A1KDM4E | |
| SCHEMBL13814477 | 0.78 | ALDH1A1 (0.64) | POLBALDH1A1HTTMMP8MMP12 | |
| SCHEMBL3791791 | 0.78 | ALDH1A1 (0.64) | POLBALDH1A1HTTMMP8MMP12 | |
| SCHEMBL3831673 | 0.76 | FABP4 (0.47) | EPHX2ALDH1A1FABP4FABP3FABP5 | |
| SCHEMBL3831668 | 0.76 | FABP4 (0.47) | EPHX2ALDH1A1FABP4FABP3FABP5 | |
| SCHEMBL3720984 | 0.75 | LMNA (0.56) | EPHX2POLBLMNAALDH1A1HTT | |
| SCHEMBL8544141 | 0.73 | PLAU (0.42) | EPHX2 | |
| SCHEMBL19976337 | 0.73 | KDM4E (0.53) | POLBLMNAALDH1A1HTTMMP8 | |
| SCHEMBL4611229 | 0.72 | MMP8 (0.56) | POLBLMNAALDH1A1MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109343-B2 | Metal catalysts and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050010049-A1 | Metal catalysts and methods for making and using same | DAVIES HUW M L (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1173278-B1 | METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME | RES FOUNDATION OFSTATE UNIVERS (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1173278-A1 | METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064583-A1 | METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010049-A1 | Metal catalysts and methods for making and using same | SLC6A3, COMT, DRD4 | EPHX2 3764/4885POLB 2171/4885LMNA 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.